Utang jangka cendhak perusahaan: AstraZeneca AB (AZN)

The short-term debt history of AstraZeneca PLC (AZN) demonstrates the trajectory of a biopharmaceutical leader investing in genetics to combat infections and cancer. The growth of the oncology portfolio and new targeted therapies are creating current momentum, with 3.23 serving as the current level of the metric. Business efficiency is being enhanced by the implementation of robotics and AI, which automate laboratory tests and accelerate the discovery of formulas.

Capital protection requires an understanding of hidden liquidity risks between reporting periods. Stable demand for AstraZeneca PLC (AZN) oncology drugs ensures a predictable cash flow, minimizing reliance on external borrowing. The GURU.Markets toolkit tracks the business's current working capital requirements through financial liabilities with a maturity of up to one year. An increase in this metric signals a risk of cash flow gaps, while a decrease indicates strengthening solvency. This is a critical marker of the asset's stability within a portfolio.